Real-World Evidence Under Consideration For Use In Interchangeable Biosimilars Applications
Executive Summary
US FDA research funded under BSUFA III will investigate what kind of safety data is needed for interchangeability. A demonstration project aimed at improving biosimilar product development efficiency and enhanced regulatory decision-making also will be part of the new regulatory science research program.
You may also be interested in...
US FDA Making BsUFA III Regulatory Science Grants Available Early
Up to $1m per year per award is available for projects that address significant issues with biosimilar or interchangeable product development.
US FDA Making BsUFA III Regulatory Science Grants Available Early
Up to $1m per year per award is available for projects that address significant issues with biosimilar or interchangeable product development.
Biosimilars Forum’s New Executive Director Faces Down Challenge Of Interchangeability Confusion
Juliana Reed, who just moved from Pfizer to head the trade group, hopes scientific advances will eventually eliminate the need for the interchangeability designation, but for now the association is educating stakeholders in preparation for the 2023 launch of Humira biosimilars.